While there was a numerical reduction in the incidence of MI (aHR, 0.88; 95% CI 0.66–1.18, P = 0.404) and stroke (aHR, 0.86; 95% CI 0.64–1.15, p = 0.299) among GLP-1 RAs users, these differences did not reach statistical significance (Fig. 2). The gene discussed is GLP1R; the disease is stroke disorder.